Abstract
Background/Aims: XIAP-associated factor 1 (XAF1) is a nuclear protein. CBP, the cAMP response element binding protein (CREB)-binding protein, plays an important role as a multifunctional transcriptional co-activator. In this investigation, we aimed to study the putative interaction between XAF1 and CBP in colon cancer cells. Methods: Expressions of XAF1 and CBP were detected by Western blot and RT-PCR. The interaction between XAF1 and CBP was investigated by the glutathione S-transferase (GST) pull-down assay, colocalization and co-immunoprecipitation analysis. Cell proliferation was examined by cell number counting. Results: Both XAF1 and CBP were co-localized in the nuclei of colon cancer cells and they demonstrated a physical interaction, as revealed by GST pull-down assay and co-immunoprecipitation analysis. CBP I peptide (residues 1–1098) was the interacting domain for XAF1 binding. The functional implication of the interaction between XAF1 and CBP was demonstrated by the finding that cell growth inhibition by XAF1 was potentiated by cotransfection with CBP. Furthermore, a reporter assay demonstrated that cotransfection with XAF1 and CBP led to marked reduction in phorbol ester 12-O-tetradecanoylphorbol-13-acetate (PMA)-stimulated adaptor-related protein complex 1 activity. Conclusions: CBP is a novel binding partner of XAF1, and the interaction between XAF1 and CBP and their functional consequence were mediated by adaptor-related protein complex 1.
Journal Section:
Original Paper
References
1.
Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG: Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol 2001;3:128–133.
[PubMed]
2.
Malik S, Roeder RG: Transcriptional regulation through mediator-like coactivators in yeast and metazoan cells. Trends Biochem Sci 2000;25:277–283.
[PubMed]
3.
Rosenfeld MG, Glass CK: Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 2001;276:36865–36868.
[PubMed]
4.
Onate SA, Tsai SY, Tsai MJ, O’Malley BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354–1357.
[PubMed]
5.
Zhu Y, Qi C, Calandra C, Rao MS, Reddy JK: Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr 1996;6:185–195.
[PubMed]
6.
Zhu Y, Qi C, Jain S, Rao MS, Reddy JK: Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 1997;272:25500–25506.
[PubMed]
7.
Lin JH, Saito T, Anderson DJ, Lance-Jones C, Jessell TM, Arber S: Functionally related motor neuron pool and muscle sensory afferent subtypes defined by coordinate ETS gene expression. Cell 1998;95:393–407.
[PubMed]
8.
Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW: A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem 1999;274:34283–34293.
[PubMed]
9.
Ko L, Cardona GR, Chin WW: Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc Natl Acad Sci USA 2000;97:6212–6217.
[PubMed]
10.
Janknecht R: The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol 2002;17:657–668.
[PubMed]
11.
Chan HM, La Thangue NB: p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001;114:2363–2373.
[PubMed]
12.
Vo N, Goodman RH: CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 2001;276:13505–13508.
[PubMed]
13.
Goodman RH, Smolik S: CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553–1577.
[PubMed]
14.
Lehrmann H, Pritchard LL, Harel-Bellan A: Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 2002;86:41–65.
[PubMed]
15.
Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH: Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993;365:855–859.
[PubMed]
16.
Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, Roberts SG, Green MR, Goodman RH: Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994;370:223–226.
[PubMed]
17.
Arany Z, Sellers WR, Livingston DM, Eckner R: E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994;77:799–800.
[PubMed]
18.
Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, Livingston DM: Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994;8:869–884.
[PubMed]
19.
Lundblad JR, Kwok RP, Laurance ME, Harter ML, Goodman RH: Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 1995;374:85–88.
[PubMed]
20.
Bannister AJ, Kouzarides T: CBP-induced stimulation of c-Fos activity is abrogated by E1A. EMBO J 1995;14:4758–4762.
[PubMed]
21.
Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z, D’Andrea A, Livingston DM: Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 1996;383:344–347.
[PubMed]
22.
Dai P, Akimaru H, Tanaka Y, Hou DX, Yasukawa T, Kanei-Ishii C, Takahashi T, Ishii S: CBP as a transcriptional coactivator of c-Myb. Genes Dev 1996;10:528–540.
[PubMed]
23.
Janknecht R, Nordheim A: Regulation of the c-fos promoter by the ternary complex factor Sap-1a and its coactivator CBP. Oncogene 1996;12:1961–1969.
[PubMed]
24.
Oelgeschlager M, Janknecht R, Krieg J, Schreek S, Luscher B: Interaction of the co-activator CBP with Myb proteins: effects on Myb-specific transactivation and on the cooperativity with NF-M. EMBO J 1996;15:2771–2780.
[PubMed]
25.
Oliner JD, Andresen JM, Hansen SK, Zhou S, Tjian R: SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein. Genes Dev 1996;10:2903–2911.
[PubMed]
26.
Trouche D, Kouzarides T: E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP. Proc Natl Acad Sci USA 1996;93:1439–1442.
[PubMed]
27.
Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ: Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997;275:523–527.
[PubMed]
28.
Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, Giordano A, Levrero M: p300 is required for MyoD-dependent cell cycle arrest and muscle-specific gene transcription. EMBO J 1997;16:369–383.
[PubMed]
29.
Sartorelli V, Huang J, Hamamori Y, Kedes L: Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol 1997;17:1010–1026.
[PubMed]
30.
Bannister AJ, Kouzarides T: The CBP co-activator is a histone acetyltransferase. Nature 1996;384:641–643.
[PubMed]
31.
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953–959.
[PubMed]
32.
Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y: A p300/CP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996;382:319–324.
[PubMed]
33.
Ionov Y, Matsui S, Cowell JK: A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci USA 2004;101:1273–1278.
[PubMed]
34.
Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R: A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 1995;374:81–84.
[PubMed]
35.
Giles RH, Peters DJ, Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 1998;14:178–183.
[PubMed]
36.
Iyer NG, Ozdag H, Caldas C: p300/CBP and cancer. Oncogene 2004;23:4225–4231.
[PubMed]
37.
Adachi M, Takayanagi R, Tomura A, Imasaki K, Kato S, Goto K, Yanase T, Ikuyama S, Nawata H: Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med 2000;343:856–862.
[PubMed]
38.
Freedman SJ, Sun ZY, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ: Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci USA 2002;99:5367–5372.
[PubMed]
39.
Leaman DW, Chawla-Sarkar M, Vyas K, Reheman M, Tamai K, Toji S, Borden EC: Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L- induced apoptosis. J Biol Chem 2002;277:28504–28511.
[PubMed]
40.
Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ozdemir A, Yi T, Williams BR, Borden EC: Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2. J Interferon Cytokine Res 2003;23:745–756.
[PubMed]
41.
Li G, Xiang Y, Sabapathy K, Silverman RH: An apoptotic signaling pathway in the interferon antiviral response mediated by RNase L and c-Jun NH2-terminal kinase. J Biol Chem 2004;279:1123–1131.
[PubMed]
42.
Ip YT, Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK) – from inflammation to development. Curr Opin Cell Biol 1998;10:205–219.
[PubMed]
43.
Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH: Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 1994;91:609–613.
[PubMed]
44.
Dong Z, Huang C, Brown RE, Ma WY: Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997;272:9962–9970.
[PubMed]
45.
Huang C, Ma WY, Young MR, Colburn N, Dong Z: Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci USA 1998;95:156–161.
[PubMed]
46.
Byun DS, Cho K, Ryu BK, Lee MG, Kang MJ, Kim HR, Chi SG: Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res 2003;63:7068–7075.
[PubMed]
© 2008 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2008
You do not currently have access to this content.
